111 related articles for article (PubMed ID: 30761750)
1. Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.
Mendis S; Beck S; Lee B; Lee M; Wong R; Kosmider S; Shapiro J; Yip D; Steel S; Nott L; Jennens R; Lipton L; Burge M; Field K; Ananda S; Wong HL; Gibbs P
Asia Pac J Clin Oncol; 2019 Jun; 15(3):136-143. PubMed ID: 30761750
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
3. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Brulé SY; Jonker DJ; Karapetis CS; O'Callaghan CJ; Moore MJ; Wong R; Tebbutt NC; Underhill C; Yip D; Zalcberg JR; Tu D; Goodwin RA
Eur J Cancer; 2015 Jul; 51(11):1405-14. PubMed ID: 25979833
[TBL] [Abstract][Full Text] [Related]
4. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
5. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer.
Ahmed S; Pahwa P; Le D; Chalchal H; Chandra-Kanthan S; Iqbal N; Fields A
Clin Colorectal Cancer; 2018 Jun; 17(2):e201-e206. PubMed ID: 29221688
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of clinicopathological features and prognosis between left-sided colon cancer and right-sided colon cancer].
Gao X; Yu G; Liu P; Hao L; Liu L; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):647-653. PubMed ID: 28643309
[TBL] [Abstract][Full Text] [Related]
7. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
8. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
Engstrand J; Nilsson H; Strömberg C; Jonas E; Freedman J
BMC Cancer; 2018 Jan; 18(1):78. PubMed ID: 29334918
[TBL] [Abstract][Full Text] [Related]
10. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
[TBL] [Abstract][Full Text] [Related]
11. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.
Gibbs P; Heinemann V; Sharma NK; Taieb J; Ricke J; Peeters M; Findlay M; Robinson B; Jackson C; Strickland A; Gebski V; Van Buskirk M; Zhao H; van Hazel G;
Clin Colorectal Cancer; 2018 Dec; 17(4):e617-e629. PubMed ID: 30033117
[TBL] [Abstract][Full Text] [Related]
12. Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival.
Lee MM; MacKinlay A; Semira C; Schieber C; Jimeno Yepes AJ; Lee B; Wong R; Hettiarachchige CKH; Gunn N; Tie J; Wong HL; Skinner I; Jones IT; Keck J; Kosmider S; Tran B; Field K; Gibbs P
Clin Colorectal Cancer; 2018 Sep; 17(3):e569-e577. PubMed ID: 29980491
[TBL] [Abstract][Full Text] [Related]
13. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
15. Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent.
Wong SF; Wong HL; Field KM; Kosmider S; Tie J; Wong R; Tacey M; Shapiro J; Nott L; Richardson G; Cooray P; Jones I; Croxford M; Gibbs P
Clin Colorectal Cancer; 2016 Sep; 15(3):e125-32. PubMed ID: 26803709
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Franko J; Shi Q; Meyers JP; Maughan TS; Adams RA; Seymour MT; Saltz L; Punt CJA; Koopman M; Tournigand C; Tebbutt NC; Diaz-Rubio E; Souglakos J; Falcone A; Chibaudel B; Heinemann V; Moen J; De Gramont A; Sargent DJ; Grothey A;
Lancet Oncol; 2016 Dec; 17(12):1709-1719. PubMed ID: 27743922
[TBL] [Abstract][Full Text] [Related]
17. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
19. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
20. Influence of primary site on metastatic distribution and survival in stage IV colorectal cancer.
Suthananthan AE; Bhandari M; Platell C
ANZ J Surg; 2018 May; 88(5):445-449. PubMed ID: 28512795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
